Fox Chase Cancer Center News

PHILADELPHIA, PA (July 24, 2014)—New research in mice adds to the growing body of evidence that an inherited mutation can increase the risk of developing cancer after exposure to asbestos – but simply having a genetic predisposition does not appear to be enough to induce the disease.

PHILADELPHIA (July 15, 2014)—Fox Chase Cancer Center has been ranked 19th among the nation’s top 50 hospitals for cancer care in U.S. News & World Report’s Best Hospitals 2014-2015 rankings. Fox Chase was also cited as high performing in the areas of nephrology, urology, and gynecology, as well as a new area – ear, nose, and throat.

Study Finds that Some Women Do Better than Current Staging Guidelines Suggest

PHILADELPHIA, PA (July 7, 2014)—New findings from Fox Chase Cancer Center paint a relatively optimistic picture of women’s chances of surviving a subset of breast cancers that have spread to the chest wall or skin, but not beyond.

PHILADELPHIA, PA (June 25, 2014)—Fox Chase physicians understand it is important for patients and their family members to receive quick and efficient access to a cancer specialist.  Not only does it help, but it gives them confidence that they are receiving the highest-quality care. For these reasons and more, Fox Chase Cancer Center launched a new Rapid Access Service, which allows patients to be seen within 24 hours of their first call to the Center or the next business day—whether or not they have a definitive diagnosis.

PHILADELPHIA, PA (June 9, 2014)—There’s much to learn from the recent release of unprecedented amounts of data from the nation’s second largest health insurer, Medicare, but only if interpreted cautiously, write two doctors at Fox Chase Cancer Center in the June 9 online edition of the Annals of Internal Medicine.

Dear Colleagues, As I am sure you have heard, Temple University and Temple Health lost a great friend this weekend with the tragic death of Lewis Katz, who served as a long-time member of the University's Board of Trustees and a member of the Boards of Temple University Health System (TUHS) and Fox Chase Cancer Center (FCCC).

CHICAGO, IL (May 30, 2014)—Fox Chase Cancer Center researchers have carried out the first retrospective analysis of adjuvant chemotherapy’s impact on overall survival in patients with stage III soft tissue sarcomas (STS), adjusted for socioeconomic status and other variables. The findings show that regardless of socioeconomic status and comorbidities, adjuvant chemotherapy improved survival by approximately 23 percent in stage III STS.

CHICAGO, IL (May 30, 2014)—The use of chemotherapy before surgery to remove ovarian cancer has increased dramatically in recent decades, particularly among certain patients, according to a new analysis from Fox Chase Cancer Center that will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology.